B Neyns1, J Sadones2, E Joosens3, F Bouttens4, L Verbeke5, J-F Baurain6, L D'Hondt7, T Strauven8, C Chaskis9, P In't Veld10, A Michotte11, J De Greve2. 1. Department of Medical Oncology, UZ Brussel, Brussels. Electronic address: bart.neyns@uzbrussel.be. 2. Department of Medical Oncology, UZ Brussel, Brussels. 3. Department of Medical Oncology, ZNA Middelheim, Antwerp. 4. Department of Radiation therapy, AZ St Lucas, Ghent. 5. Department of Radiation therapy, OLV Aalst, Aalst. 6. Department of Medical Oncology, Cliniques Universitaires St Luc, Brussels. 7. Department of Medical Oncology, Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi. 8. Department of Neurology, Sint-Augustinus, Antwerp. 9. Department of Neurosurgery. 10. Department of Experimental pathology. 11. Department of Neurology; Department of Neuropathology, UZ Brussel, Brussels, Belgium.
Abstract
BACKGROUND: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and chemotherapy. PATIENTS AND METHODS: In this two-arm, open-label, phase II study patients were stratified according to their epidermal growth factor receptor (EGFR) gene amplification status. Cetuximab was administered intravenously at a dose of 400 mg/m(2) on week 1 followed by weekly dose of 250 mg/m(2). The primary end point for this study was the response rate in both study arms separately. RESULTS: Fifty-five eligible patients (28 with and 27 without EGFR amplification) tolerated cetuximab well. Three patients (5.5%) had a partial response and 16 patients (29.6%) had stable disease. The median time to progression was 1.9 months [95% confidence interval (CI) 1.6-2.2 months]. Whereas the progression-free survival (PFS) was <6 months in the majority (n = 50/55) of patients, five patients (9.2%) had a PFS on cetuximab of >9 months. Median overall survival was 5.0 months (95% CI 4.2-5.9 months). No significant correlation was found between response, survival and EGFR amplification. CONCLUSIONS: Cetuximab was well tolerated but had limited activity in this patient population with progressive HGG. A minority of patients may derive a more durable benefit but were not prospectively identified by EGFR gene copy number.
BACKGROUND: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with recurrent high-grade glioma (HGG) after failure of surgery, radiation therapy, and chemotherapy. PATIENTS AND METHODS: In this two-arm, open-label, phase II study patients were stratified according to their epidermal growth factor receptor (EGFR) gene amplification status. Cetuximab was administered intravenously at a dose of 400 mg/m(2) on week 1 followed by weekly dose of 250 mg/m(2). The primary end point for this study was the response rate in both study arms separately. RESULTS: Fifty-five eligible patients (28 with and 27 without EGFR amplification) tolerated cetuximab well. Three patients (5.5%) had a partial response and 16 patients (29.6%) had stable disease. The median time to progression was 1.9 months [95% confidence interval (CI) 1.6-2.2 months]. Whereas the progression-free survival (PFS) was <6 months in the majority (n = 50/55) of patients, five patients (9.2%) had a PFS on cetuximab of >9 months. Median overall survival was 5.0 months (95% CI 4.2-5.9 months). No significant correlation was found between response, survival and EGFR amplification. CONCLUSIONS:Cetuximab was well tolerated but had limited activity in this patient population with progressive HGG. A minority of patients may derive a more durable benefit but were not prospectively identified by EGFR gene copy number.
Authors: Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao Journal: Cancer Res Date: 2010-07-20 Impact factor: 12.701
Authors: Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee Journal: Carcinogenesis Date: 2013-03-01 Impact factor: 4.944
Authors: Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson Journal: CA Cancer J Clin Date: 2010 May-Jun Impact factor: 508.702
Authors: S Harrison Farber; Aladine A Elsamadicy; Ahmet Fatih Atik; Carter M Suryadevara; Pakawat Chongsathidkiet; Peter E Fecci; John H Sampson Journal: Expert Opin Drug Saf Date: 2017-01-03 Impact factor: 4.250
Authors: Thomas G Weber; Franz Osl; Anja Renner; Thomas Pöschinger; Stefanie Galbán; Alnawaz Rehemtulla; Werner Scheuer Journal: Cancer Res Date: 2014-02-07 Impact factor: 12.701